Comparative Pharmacology
Head-to-head clinical analysis: ALPHACAINE HYDROCHLORIDE W EPINEPHRINE versus LABETALOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHACAINE HYDROCHLORIDE W EPINEPHRINE versus LABETALOL.
ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE vs Labetalol
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine, an amide-type local anesthetic, stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse initiation and conduction. Epinephrine acts as a vasoconstrictor via alpha-1 adrenergic receptor agonism, reducing local blood flow and prolonging anesthetic effect.
Labetalol is a racemic mixture of four stereoisomers, each with distinct activity. It is a non-selective beta-adrenergic antagonist (blocking beta1 and beta2 receptors) and a selective alpha1-adrenergic antagonist. The alpha1 blockade causes vasodilation and reduces peripheral vascular resistance, while beta blockade reduces heart rate and myocardial contractility, leading to decreased blood pressure without significant reflex tachycardia.
1-2 mL of 2% lidocaine (20-40 mg) with epinephrine 1:100,000 (0.01-0.02 mg epinephrine) injected locally; maximum single dose 7 mg/kg lidocaine (7 mL/kg of 0.1% solution equivalent).
Oral: 200-1200 mg/day in 2 divided doses; initial 100 mg twice daily. IV: 20 mg bolus over 2 minutes, may repeat 40 mg at 10-minute intervals. Max cumulative dose: 300 mg.
None Documented
Clinical Note
moderateLabetalol + Digitoxin
"Labetalol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateLabetalol + Deslanoside
"Labetalol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateLabetalol + Acetyldigitoxin
"Labetalol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateLabetalol + Ouabain
"Labetalol may increase the bradycardic activities of Ouabain."
None Documented
Alphacaine: 1.5-2 hours; epinephrine: 2-3 minutes. Clinical context: The duration of local anesthesia is prolonged by epinephrine-induced vasoconstriction, not by the half-life of alphacaine.
6-8 hours (terminal elimination half-life); may be prolonged in hepatic impairment, unchanged in renal impairment.
Primarily renal excretion of metabolites and unchanged drug; <5% excreted unchanged in urine. Biliary excretion accounts for a minor fraction.
Renal (55-60% as unchanged drug and metabolites); biliary/fecal (minor, approximately 5-10%); remainder metabolized in liver.
Category A/B
Category A/B
Alpha/Beta Agonist
Alpha/Beta-Blocker